1. Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor.
Expression of immune checkpoint molecules on leukocytes and tumor cells at baseline and in response to selinexor. A and B, Selinexor alters the expression of PDCD1, CTLA4, and XPO1 on immune and tumor cells. A, Peripheral blood leukocytes were cultured in selinexor (30–300 nmol/L) for up to 24 hours and mRNA transcript levels of PDCD1, CTLA4, and XPO1 assessed via qPCR, relative to the level in untreated cells. n = 6 donors. B, Melanoma cells or (C) human breast cancer (MDA-MB-468), prostate cancer (PC3), and sarcoma cells (ASPS-KY) were cultured in vehicle or up to 1 μmol/L selinexor for 24 hours and CD274 mRNA transcript levels assessed via qPCR, relative to the untreated cells. n = 9 (B) or 3 (C) independent biological replicates. Mean ± SD. D, Melanoma cells express PD-L1 on the cell surface. Surface expression of PD-L1 on human and murine melanoma cells was assessed by flow cytometry. Gray histogram, isotype control; open histogram, anti-PD-L1. Representative of three independent experiments. *, P < 0.05; **, P < Mean ± SD.
Matthew R. Farren et al. Mol Cancer Ther 2017;16:
©2017 by American Association for Cancer Research